Search results for "From ACP Journal Club"
Some glucose-lowering drugs reduce risk for major adverse cardiac events
An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
https://diabetes.acponline.org/archives/2020/08/14/7.htm
14 Aug 2020
In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years
Despite the lack of observed benefit in this analysis, primary care physicians should continue to operate under the reasonable assumption that addressing cardiovascular (CV) risk factors improves longevity, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/05/08/6.htm
8 May 2020
Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers
An industry-funded randomized trial showed that topical wound oxygen therapy is efficacious, but more data on effectiveness, outcomes, and cost are needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/04/10/6.htm
10 Apr 2020
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
The data suggest that renoprotection from sodium-glucose cotransporter-2 (SGLT-2) inhibitors may not require the presence of diabetes or albuminuria and may be effective even in patients with worse renal function, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/03/13/6.htm
13 Mar 2020
In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach
Despite this study's findings, clinicians should continue to follow guidelines and use metformin as the first-line drug intervention, then select from other drug classes when there is a compelling indication, advised an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/03/13/7.htm
13 Mar 2020
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/02/14/6.htm
14 Feb 2020
In acute ischemic stroke with hyperglycemia, intensive vs standard glucose control did not improve 90-day outcomes
Several factors, including high rates of reperfusion therapy and early hospital discharge, may explain why this trial found no benefit from intensive glucose control after stroke, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/01/10/7.htm
10 Jan 2020
SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
An ACP Journal Club commentary called the results of this real-world, retrospective study reassuring regarding concerns about associations of urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
https://diabetes.acponline.org/archives/2020/01/10/8.htm
10 Jan 2020
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019
Studies show benefits of glucagon-like peptide-1 receptor agonists
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
https://diabetes.acponline.org/archives/2019/10/11/7.htm
11 Oct 2019